Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability

Baricitinib (BTB) is an orally administered Janus kinase inhibitor, therapeutically used for the treatment of rheumatoid arthritis. Recently it has also been approved for the treatment of COVID-19 infection. In this study, four different BTB-loaded lipids (stearin)-polymer (Poly(d,l-lactide-co-glyco...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwer, Md. Khalid, Ali, Essam A., Iqbal, Muzaffar, Ahmed, Mohammed Muqtader, Aldawsari, Mohammed F., Saqr, Ahmed Al, Ansari, Mohd Nazam, Aboudzadeh, M. Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746631/
https://www.ncbi.nlm.nih.gov/pubmed/35011397
http://dx.doi.org/10.3390/molecules27010168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746631/
https://www.ncbi.nlm.nih.gov/pubmed/35011397
http://dx.doi.org/10.3390/molecules27010168

Ejemplares similares